Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors

Peter M. Moyle, Wei Dai, Tzu-Yu Liu, Waleed M. Hussein, Pirashanthini Maruthayanar, James W. Wells, Nigel A.J. McMillan, Mariusz Skwarczynski, Istvan Toth
  • Bioorganic & Medicinal Chemistry Letters, December 2015, Elsevier
  • DOI: 10.1016/j.bmcl.2015.10.049

Semisynthetic, recombinant, non-oncogenic HPV-16 E7 lipoprotein vaccine against cervical cancer

What is it about?

We developed a non-oncogenic recombinant human papillomavirus type-16 (HPV-16) E7 protein, incorporating the PADRE1024.03 universal T helper epitope, and site-specifically conjugated a chemically synthesised Pam2Cys to the proteins C-terminus. This defined protein was assessed for its capacity to clear a cervical cancer model in mice.

Why is it important?

Cervical cancer is an important cancer in females, with ~ 50% of cervical cancers associated with HPV-16 infection. We have created a defined subunit vaccine, with a built in adjuvant, that could serve as a platform for the further development of commercial vaccines against HPV-16 associated cervical cancers.

Perspectives

Dr Peter Michael Moyle (Author)
University of Queensland

This paper provides a lead molecule which could be further modified through the addition of additional HPV proteins to generate a vaccine for the treatment of various HPV associated cancers.

The following have contributed to this page: Dr Peter Michael Moyle and Miss Wei WD Dai